FDA Finalizes Guidance On Clinical Holds Due To Investigator Misconduct
FDA's final guidance on clinical holds due to clinical investigator misconduct drops some discussion of financial disclosure issues
You may also be interested in...
Violations of FDA's financial disclosure requirements would be unlikely to lead to a clinical hold decision, FDA says in a draft guidance on investigator misconduct and clinical holds
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials